Inventor · disambiguated record
David L. Bourdet
Also filed as: BOURDET DAVID L
4 granted patents·2 pending applications·6 citations·filing 2018–2024
69Inventor score
Files withTHERAVANCE BIOPHARMA R&D IP LLC6
Top patents by PatentIndex Score
6 records- 0189US11718591B2Crystalline (2S,4R)-5-(5′-chloro-2′-fluoro-[1,1′-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2- methylpentanoic acid and uses thereofTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2021·Granted Aug 8, 2023·1 cites·20 claims
- 0287US10472335B2Crystalline(2S,4R)-5-(5′-chloro-2′-fluoro-[1,1′-bipheny]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereofTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2018·Granted Nov 12, 2019·4 cites·15 claims
- 0385US12351561B2Crystalline (2S,4R)-5-(5'-chloro-2'-fluoro-[1,1'-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereofTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2024·Granted Jul 8, 2025·0 cites·63 claims
- 0478US11471442B2Administration of gut-selective JAK3 inhibitorTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2021·Granted Oct 18, 2022·1 cites·20 claims
- 0562US2025288561A1Nezulcitinib for delivery by nebulized oral inhalationTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2023·Application pending·0 cites
- 0651US2023372318A1Methods for treating a subject having multiple system atrophyTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2023·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when David L. Bourdet files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →